Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2004-04-22 | Mr. McNab is a co-founder and chairman of several companies in life sciences and medical devices. He has an M.B.A. and a B.A. |
| 2005-04-20 | Mr. McNab received an M.B.A. from the University of North Carolina and a B.A. from Davidson College. |
| 2006-04-13 | Mr. McNab received an M.B.A. from the University of North Carolina and a B.A. from Davidson College. |
| 2007-04-13 | Mr. McNab received a B.A. in economics from Davidson College and an M.B.A. from the University of North Carolina at Chapel Hill. |
| 2008-04-11 | Mr. McNab received a B.A. in economics from Davidson College and an M.B.A. from the University of North Carolina at Chapel Hill. |
| 2009-04-17 | Mr. McNab received a B.A. in economics from Davidson College and an M.B.A. from the University of North Carolina at Chapel Hill. |
| 2010-04-16 | Mr. McNab received a B.A. in economics from Davidson College and an M.B.A. from the University of North Carolina at Chapel Hill. We believe that Mr. McNab’s qualifications to serve on our board include his decades of experience as chairman, founder and/or Chief Executive Officer of various pharmaceutical, medical device and biotechnology companies, including his experience as co-founder of one of our predecessor companies. |
| 2011-04-19 | Mr. McNab received a B.A. in economics from Davidson College and an M.B.A. from the University of North Carolina at Chapel Hill. He has experience as chairman and CEO of pharmaceutical and medical device companies. |
| 2012-04-13 | Mr. McNab received a B.A. in economics from Davidson College and an M.B.A. from the University of North Carolina at Chapel Hill. We believe that Mr. McNab’s qualifications to serve on our board include his decades of experience as chairman, founder and/or Chief Executive Officer of various pharmaceutical, medical device and biotechnology companies. |
| 2013-04-16 | Mr. McNab received a B.A. in economics from Davidson College and an M.B.A. from the University of North Carolina at Chapel Hill. |
| 2014-04-09 | Mr. McNab has served as Chairman of our board since May 2002. Since 1998, Mr. McNab has served as Chief Executive Officer and Chairman of Palmetto Pharmaceuticals, Inc., a privately-held drug discovery company. |
| 2015-04-15 | Mr. McNab received a B.A. in economics from Davidson College and an M.B.A. from the University of North Carolina at Chapel Hill. |
| 2016-04-05 | Mr. McNab received a B.A. in economics from Davidson College and an M.B.A. from the University of North Carolina at Chapel Hill. |
| 2017-04-04 | Mr. McNab received a B.A. in economics from Davidson College and an M.B.A. from the University of North Carolina at Chapel Hill. We believe that Mr. McNab’s qualifications to serve on our board include his decades of experience as chairman, founder and/or Chief Executive Officer of various pharmaceutical, medical device and biotechnology companies, including his experience as co-founder of one of our predecessor companies. |
| Filing Date | Source Excerpt |
|---|---|
| 2015-07-20 | James R. McNab, Jr. has served since 1998 as chief executive officer and chairman of Palmetto Pharmaceuticals, Inc., a privately-held drug discovery company he founded. He has been a chairman of the board of directors of Curis, Inc. (Nasdaq:CRIS), an oncology focused biotechnology company, since May 2002. Since 2009, Mr. McNab has served as executive chairman of FirstString Research, Inc., a privately-held biopharmaceutical company, and as chief executive officer of JT Pharmaceuticals, Inc., a privately-held drug discovery company. Mr. McNab has co-founded several privately-held companies, including Sontra Medical Corporation, a drug delivery company, and Parker Medical Associates, a manufacturer and worldwide supplier of orthopedic and sports-related products. He received a B.A. in economics from Davidson College and an M.B.A. from the University of North Carolina at Chapel Hill. Based on Mr. McNab's extensive management experience in the pharmaceutical industry, our Board believes that Mr. McNab has the appropriate set of skills to serve as a member of the Board. |
| 2016-06-29 | The purpose of the governance committee is to assist the Board in identifying qualified individuals to become board members, in determining the composition of the Board and in monitoring the process to assess Board effectiveness. The governance committee currently consists of Eurelio M. Cavalier and James R. McNab, Jr., each of whom meets the independence requirements and standards currently established by the Nasdaq. |
| 2017-06-26 | James R. McNab, Jr. has served since 1998 as chief executive officer and chairman of Palmetto Pharmaceuticals, Inc., a privately-held drug discovery company he founded. Based on Mr. McNab’s extensive management experience in the pharmaceutical industry, our Board believes that Mr. McNab has the appropriate set of skills to serve as a member of the Board. The audit committee currently consists of Joseph A. Akers (chair), M. David MacFarlane and James R. McNab, Jr. The governance committee currently consists of James R. McNab, Jr. (chair), M. David MacFarlane and Rajinder Kumar. James R. McNab, Jr. 2016 Total Compensation $54,583. |
| 2018-07-02 | James R. McNab, Jr. has served since June 2014 as chief executive officer of JT Pharmaceuticals, Inc. The audit committee currently consists of Joseph A. Akers (chair), M. David MacFarlane and James McNab. The governance committee consists of James R. McNab, Jr., Rajinder Kumar and M. David MacFarlane. The following table summarizes compensation that our non-employee directors earned during 2017 for services as members of our Board. James R. McNab, Jr. earned $97,627 in total compensation. |
| 2018-12-20 | James R. McNab, Jr. Fees Earned or Paid in Cash ($): $57,500 Total ($): $57,500 |
| 2019-11-20 | James R. McNab, Jr. (75) has served since June 2014 as chief executive officer of JT Pharmaceuticals, Inc., a privately-held drug discovery company he founded. ... The audit committee was formed in compliance with Section 3(a)(58)(A) of the Securities Exchange Act of 1934 (the “Exchange Act”) and currently consists of Joseph A. Akers (chair), M. David MacFarlane and James R. McNab, Jr., each of whom meets the independence requirements and standards currently established by Nasdaq and the SEC. ... The nominating committee consists of James R. McNab, Jr., Rajinder Kumar and M. David MacFarlane who meet the independence requirements and standards currently established by Nasdaq. |
| 2020-01-31 | James R. McNab, Jr.(8) Includes (i) 6,138 shares issuable upon exercise of outstanding options and (ii) 33,334 shares issuable upon exercise of outstanding warrants. |
| 2020-05-22 | Name and Address of Beneficial Owner(1) James R. McNab, Jr.(7) |
| 2020-11-02 | James R. McNab, Jr.(7) Includes (i) 6,138 shares issuable upon exercise of outstanding options and (ii) 33,334 shares issuable upon exercise of outstanding warrants. |
| 2020-11-25 | James R. McNab, Jr. (76) has served since June 2014 as chief executive officer of JT Pharmaceuticals, Inc., a privately-held drug discovery company he founded. The audit committee currently consists of Joseph A. Akers (chair), M. David MacFarlane, Ph.D. and James R. McNab, Jr., each of whom meets the independence requirements and standards currently established by Nasdaq and the SEC. The nominating committee consists of Joseph A. Akers, M. David MacFarlane, Ph.D. and Scott A. Smith (chair), each of whom meets the independence requirements and standards currently established by Nasdaq. James R. McNab, Jr. earned $57,500. |
| 2021-11-05 | James R. McNab, Jr. (77) has served since June 2014 as chief executive officer of JT Pharmaceuticals, Inc., a privately-held drug discovery company he founded. ... The audit committee was formed in compliance with Section 3(a)(58)(A) of the Securities Exchange Act of 1934 (the “Exchange Act”) and currently consists of Joseph A. Akers (chair), M. David MacFarlane, Ph.D. and James R. McNab, Jr., each of whom meets the independence requirements and standards currently established by Nasdaq and the SEC. ... The compensation committee currently consists of Joseph A. Akers, M. David MacFarlane, Ph.D. (chair) and James R. McNab, Jr., each of whom meets the independence requirements and standards currently established by Nasdaq. ... The nominating committee consists of Joseph A. Akers, M. David MacFarlane, Ph.D. and James R. McNab, Jr. (chair), each of whom meets the independence requirements and standards currently established by Nasdaq. |
| 2023-05-19 | James R. McNab, Jr. is a member of the Compensation Committee and the Nominating and Governance Committee... James R. McNab, Jr. 2022 compensation total $71,359. |
Data sourced from SEC filings. Last updated: 2026-02-03